Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > News & Updates > Regulatory Updates > Drugs > Registration Board directed manufacturers to follow USP Monograph for Ciprofloxacin Oral Suspension

Registration Board directed manufacturers to follow USP Monograph for Ciprofloxacin Oral Suspension

Asad Ullah Drugs July 25, 2024July 25, 2024
Circular-for-Ciprofloxacin-for-Oral-suspensionDownload

Share this:

  • Twitter
  • Facebook
  • ← Minutes of 49th Meeting of Clinical Studies Committee
  • DRAP Pharmacovigilance Newsletter-August 2024 →
  • Drugs
  • Medical Devices
  • Alternative Medicines
  • Controlled Substances
  • Licensing and Inspections
  • Clinical Trials
  • Pharmacovigilance
  • Advertisements
  • General

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem